Amendments to the Claims:

1-57. (canceled)

58. (currently amended) An isolated nucleic acid having at least 80% nucleic acid sequence identity to:

~~(a) a nucleic acid sequence encoding the polypeptide shown in Figure 142 (SEQ ID NO:352);~~

~~(b) a nucleic acid sequence encoding the polypeptide shown in Figure 142 (SEQ ID NO:352), lacking its associated signal peptide;~~

~~(c) a nucleic acid sequence encoding the extracellular domain of the polypeptide~~ of ~~shown in Figure 142 (SEQ ID NO:352~~;

~~(d) a nucleic acid sequence encoding the extracellular domain of the polypeptide shown in Figure 142 (SEQ ID NO:352), lacking its associated signal peptide;~~

[[(e)]] the nucleic acid sequence of SEQ ID NO:351 ~~shown in Figure 141 (SEQ ID NO:351);~~

~~(f) the full-length coding sequence of the nucleic acid sequence shown in Figure 141 (SEQ ID NO:351); or~~

~~(g) the full-length coding sequence of the cDNA deposited under ATCC accession number 209905~~

wherein the encoded polypeptide has fetal hemoglobin inducing activity.

59. (currently amended) The isolated nucleic acid of Claim 58 having at least 85% nucleic acid sequence identity to:

~~(a) a nucleic acid sequence encoding the polypeptide shown in Figure 142 (SEQ ID NO:352);~~

~~(b) a nucleic acid sequence encoding the polypeptide shown in Figure 142 (SEQ ID NO:352), lacking its associated signal peptide;~~

~~(c) a nucleic acid sequence encoding the extracellular domain of the polypeptide~~ of ~~shown in Figure 142 (SEQ ID NO:352;~~

~~(d) a nucleic acid sequence encoding the extracellular domain of the polypeptide shown in Figure 142 (SEQ ID NO:352), lacking its associated signal peptide;~~

[[(e)]] the nucleic acid sequence of SEQ ID NO:351 ~~shown in Figure 141 (SEQ ID NO:351);~~

~~(f) the full-length coding sequence of the nucleic acid sequence shown in Figure 141 (SEQ ID NO:351); or~~

~~(g) the full-length coding sequence of the cDNA deposited under ATCC accession number 209905~~

wherein the encoded polypeptide has fetal hemoglobin inducing activity.

60. (currently amended) The isolated nucleic acid of Claim 58 having at least 90% nucleic acid sequence identity to:

~~(a) a nucleic acid sequence encoding the polypeptide shown in Figure 142 (SEQ ID NO:352);~~

~~(b) a nucleic acid sequence encoding the polypeptide shown in Figure 142 (SEQ ID NO:352), lacking its associated signal peptide;~~

~~(c) a nucleic acid sequence encoding the extracellular domain of the polypeptide~~ of ~~shown in Figure 142 (SEQ ID NO:352;~~

~~(d) a nucleic acid sequence encoding the extracellular domain of the polypeptide shown in Figure 142 (SEQ ID NO:352), lacking its associated signal peptide;~~

[[(e)]] the nucleic acid sequence of SEQ ID NO:351 ~~shown in Figure 141 (SEQ ID NO:351);~~

~~(f) the full-length coding sequence of the nucleic acid sequence shown in Figure 141 (SEQ ID NO:351); or~~

~~(g) the full-length coding sequence of the cDNA deposited under ATCC accession number 209905~~

wherein the encoded polypeptide has fetal hemoglobin inducing activity.

61. (currently amended) The isolated nucleic acid of Claim 58 having at least 95% nucleic acid sequence identity to:

~~(a) a nucleic acid sequence encoding the polypeptide shown in Figure 142 (SEQ ID NO:352);~~

~~(b) a nucleic acid sequence encoding the polypeptide shown in Figure 142 (SEQ ID NO:352), lacking its associated signal peptide;~~

~~(c) a nucleic acid sequence encoding the extracellular domain of the polypeptide~~ of ~~shown in Figure 142 (SEQ ID NO:352~~;

~~(d) a nucleic acid sequence encoding the extracellular domain of the polypeptide shown in Figure 142 (SEQ ID NO:352), lacking its associated signal peptide;~~

[[(e)]] the nucleic acid sequence of SEQ ID NO:351 ~~shown in Figure 141 (SEQ ID NO:351);~~

~~(f) the full-length coding sequence of the nucleic acid sequence shown in Figure 141 (SEQ ID NO:351); or~~

~~(g) the full-length coding sequence of the cDNA deposited under ATCC accession number 209905~~

wherein the encoded polypeptide has fetal hemoglobin inducing activity.

62. (currently amended) The isolated nucleic acid of Claim 58 having at least 99% nucleic acid sequence identity to:

~~(a) a nucleic acid sequence encoding the polypeptide shown in Figure 142 (SEQ ID NO:352);~~

~~(b) a nucleic acid sequence encoding the polypeptide shown in Figure 142 (SEQ ID NO:352), lacking its associated signal peptide;~~

~~(c) a nucleic acid sequence encoding the extracellular domain of the polypeptide of shown in Figure 142 (SEQ ID NO:352;~~

~~(d) a nucleic acid sequence encoding the extracellular domain of the polypeptide shown in Figure 142 (SEQ ID NO:352), lacking its associated signal peptide;~~

[[(e)]] the nucleic acid sequence of SEQ ID NO:351 ~~shown in Figure 141 (SEQ ID NO:351);~~

~~(f) the full-length coding sequence of the nucleic acid sequence shown in Figure 141 (SEQ ID NO:351); or~~

~~(g) the full-length coding sequence of the cDNA deposited under ATCC accession number 209905~~

wherein the encoded polypeptide has fetal hemoglobin inducing activity.

63. (currently amended) An isolated nucleic acid comprising:

(a) a nucleic acid sequence encoding the polypeptide of SEQ ID NO:352 ~~shown in Figure 142 (SEQ ID NO:352)~~;

(b) a nucleic acid sequence encoding the polypeptide of SEQ ID NO:352 ~~shown in Figure 142 (SEQ ID NO:352)~~, lacking its associated signal peptide;

~~(c) a nucleic acid sequence encoding the extracellular domain of the polypeptide shown in Figure 142 (SEQ ID NO:352);~~

~~(d) a nucleic acid sequence encoding the extracellular domain of the polypeptide shown in Figure 142 (SEQ ID NO:352), lacking its associated signal peptide;~~

[[(e)]] (c) the nucleic acid sequence of SEQ ID NO:351 ~~shown in Figure 141 (SEQ ID NO:351)~~;

[[(f)]] (d) the full-length coding sequence of the nucleic acid sequence of SEQ ID NO:351 ~~shown in Figure 141 (SEQ ID NO:351)~~; or

[[(g)]] (e) the full-length coding sequence of the cDNA deposited under ATCC accession number 209905.

64. (currently amended) The isolated nucleic acid of Claim 63 comprising a nucleic acid sequence encoding the polypeptide of SEQ ID NO:352 ~~shown in Figure 142 (SEQ ID NO:352)~~.

65. (currently amended) The isolated nucleic acid of Claim 63 comprising a nucleic acid sequence encoding the polypeptide of SEQ ID NO:352 ~~shown in Figure 142 (SEQ ID NO:352)~~, lacking its associated signal peptide.

66. (canceled)

67. (canceled)

68. (currently amended) The isolated nucleic acid of Claim 63 comprising the nucleic acid sequence of SEQ ID NO:351 ~~shown in Figure 141 (SEQ ID NO:351)~~.

69. (currently amended) The isolated nucleic acid of Claim 63 comprising the full-length coding sequence of the nucleic acid sequence of SEQ ID NO:351 ~~shown in Figure 141 (SEQ ID NO:351)~~.

70. (previously presented) The isolated nucleic acid of Claim 63 comprising the full-length coding sequence of the cDNA deposited under ATCC accession number 209905.

71. (canceled)

72. (canceled)

73. (canceled)

74. (previously presented) A vector comprising the nucleic acid of Claim 58 or 63.

75. (previously presented) The vector of Claim 74, wherein said nucleic acid is operably linked to control sequences recognized by a host cell transformed with the vector.

76. (previously presented) A host cell comprising the vector of Claim 74.

77. (previously presented) The host cell of Claim 76, wherein said cell is a CHO cell, an *E. coli* or a yeast cell.